瞬时弹性成像监测非酒精性脂肪性肝病合并代偿期进展性慢性肝病患者肝脏相关事件发生与生存
该回顾性分析纳入6个国家1039例非酒精性脂肪性肝病(NAFLD)且组织学F3-F4纤维化或肝硬度测量(LSM)>10 kPa的患者,中位随访35个月。基线LSM与肝脏失代偿、肝细胞癌(HCC)及肝病相关死亡独立相关;533例有随访LSM的患者中,LSM变化与肝脏失代偿、HCC、全因死亡及肝病相关死亡独立相关。
要点
- 基线LSM与肝脏失代偿、HCC及肝病相关死亡独立相关。
- 随访LSM变化与肝脏失代偿、HCC、全因死亡及肝病相关死亡独立相关。
- NAFLD合并代偿期进展性慢性肝病患者可用LSM及其变化评估肝脏相关事件和死亡风险。
核心结论
- 在NAFLD合并代偿期进展性慢性肝病患者中,基线LSM和LSM变化与肝脏相关事件及死亡风险相关。
研究设计与样本
- 回顾性分析纳入6个国家医疗中心的NAFLD连续患者1039例,均有组织学F3-F4纤维化诊断和/或LSM>10 kPa,随访至少6个月。
- LSM采用FibroScan的M或XL探头测量,记录基线和末次随访检查前1年内的数值。
- LSM变化分类为:改善(降低超过20%)、稳定(降低20%至升高20%)、恶化(升高20%及以上)。
- 中位随访35个月(四分位距19-63个月),记录肝脏事件(如肝脏失代偿、腹水、脑病、静脉曲张出血、黄疸或HCC)及全因和肝病相关死亡。
主要发现
- 基于Cox回归分析,基线LSM与肝脏失代偿发生独立相关(HR 1.03;95%CI 1.02-1.04;P<.001)。
- 基线LSM与HCC发生独立相关(HR 1.03;95%CI 1.00-1.04;P=.003)。
- 基线LSM与肝病相关死亡独立相关(HR 1.02;95%CI 1.02-1.03;P=.005)。
- 533例有随访LSM的患者中,LSM变化与肝脏失代偿独立相关(HR 1.56;95%CI 1.05-2.51;P=.04)。
- 533例有随访LSM的患者中,LSM变化与HCC独立相关(HR 1.72;95%CI 1.01-3.02;P=.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events. METHODS: We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3-F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19-63 months). RESULTS: Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02-1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00-1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02-1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05-2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01-3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11-2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10-3.38; P = .02). CONCLUSIONS: In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.
引用
- Petta S, Sebastiani G, Viganò M, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32621970. doi:10.1016/j.cgh.2020.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。